PathoCare Holdings, Inc.—the parent company of medical diagnostics innovator PathoCare, LLC (a leader in the Lab-on-a-Chip non-invasive Point of Care diagnostics)—has developed a set of tests backed by a revolutionary Raman spectroscopy-based testing platform that is underpinned by 17 patents and adaptive AI. Today, the company announced that it has accepted a third-party tender offer involving the secondary purchase of shares from an early investor. While specific transaction details remain undisclosed, the agreement reflects a company valuation of $500 million.
The $500 million valuation assigned to PathoCare Holdings, Inc. in connection with the tender offer was independently determined by Lehrer Financial (a nationally recognized economic and financial consulting firm based in Houston, Texas, with over forty years of experience providing high-precision business valuations). Lehrer Financial has built a reputation for analytical rigor and defensible methodologies across industries—including healthcare, banking, real estate, and emerging technologies.
The transaction was structured in response to shareholder interest in early liquidity and estate planning, and was designed to support the evolving needs of long-term investors. A private institutional investor acquired a portion of PathoCare Holdings’ outstanding equity in a tender offer authorized by the company’s board of directors.
“This tender offer reflects continued confidence in the long-term value and market potential of PathoCare’s breakthrough diagnostics platform,” said L. Mychal Jefferson, Chairman of PathoCare Holdings. “As we scale our technology, we remain committed to supporting the needs of our investors, while enabling mission-critical product development.”
In parallel with the tender offer, PathoCare Holdings is reviewing opening a new private equity financing round to raise up to $25 million from qualified institutional investors. The capital will be used to accelerate the development, engineering, and regulatory readiness of the company’s flagship product—the PathoWand, a next-generation point-of-care diagnostic device utilizing Raman spectroscopy and artificial intelligence for real-time pathogen detection.
This initiative follows a prior $150 million venture investment, acquisition and recapitalization led by Hamershlag Private Capital Management Limited, that resulted in Hamershlag Private acquiring seventy percent (70%) and the original founders receiving thirty percent (30%) of the of the newly restructured and recapitalized company. This marks another major milestone in PathoCare’s transformation from a research-stage venture to a commercial healthcare technology platform.
Lehrer Financial specializes in non-public company valuations, intellectual property analysis, and merger & acquisition consulting, with expertise extending into litigation support and medical economics. Their valuation process included a comprehensive review of PathoCare’s intellectual property portfolio, operating models, industry forecasts, and growth trajectory within the diagnostic testing sector.
Lehrer’s valuation is supported by robust market and financial analysis and is designed to meet the highest professional standards—providing a credible foundation for both private equity transactions and shareholder decisions. The firm’s long-standing reputation for producing concise, defensible, and expert-backed assessments ensured that PathoCare’s corporate valuation could stand up to scrutiny from institutional investors and strategic advisors alike.
